The Max Foundation shared a post on LinkedIn:
“We’re pleased to share that the NEJM Group New England Journal of Medicine has published our ‘Letter to the Editor‘ on treatment-free remission for chronic myeloid leukemia (CML) in low- and middle-income countries! It was written in collaboration with Dr. Jerry Radich from the Fred Hutch Cancer Research Center and partner physicians from Armenia, the Dominican Republic, El Salvador, Ethiopia, Honduras, India, Kenya, and Paraguay.
For many patients with CML, achieving treatment-free remission represents an important milestone: the possibility of safely stopping treatment. Our letter highlights that it can be achieved in resource-limited settings when patients have access to structured molecular monitoring and supportive care from healthcare providers and the Max team.
Today, more than 150 patients across 10 countries have successfully stopped treatment. That means they don’t have to worry about daily medication, allowing them more time to focus on education, work, and spending time with their loved ones.
We’re grateful to the physicians, patients, and partners who made this work possible and who continue to advance equitable access to cancer care around the world.”
Other articles about The Max Foundation on OncoDaily.